Videos

Karim Fizazi, MD, discusses findings from the phase 3 TALAPRO-2 trial which support the recent FDA approval of talazoparib plus enzalutamide in homologous recombination repair gene-mutated metastatic castration resistant prostate cancer.

Ruchi Garg, MD, discusses current treatment options and strategies being utilized for patients with endometrial cancer.

Benjamin Besse, MD, PhD, discusses the main findings and next steps of the phase 1/1b CHRYSALIS-2 study in EGFR-mutated non–small cell lung cancer.

Yazan Samhouri, MD, discusses the latest advancements in the diffuse large B-cell lymphoma treatment landscape.

Bradley J. Monk, MD, FACS, FACOG, explains the implications of the phase 3 KEYNOTE-826 clinical trial.

Expert perspectives on the current treatment paradigm for patients diagnosed with locally advanced or metastatic urothelial carcinoma.

Joshua K. Sabari, MD, discusses LY3537982 for patients with KRAS G12C-mutant advanced solid tumors.

Samer A. Srour, MD, discusses research on Orca-Q for patients undergoing haploidentical allogeneic hematopoietic stem cell transplantation.

Laura A. Dawson, MD, FRCPC, discusses key takeaways from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib vs sorafenib alone in patients with hepatocellular carcinoma.

Expert oncologist Alicia Morgans, MD, MPH, shares her hope for future improvements in metastatic castration-resistant prostate cancer management as the landscape continues to evolve.

Comprehensive insight on the real-world use of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer management, given patient, disease, and logistical concerns.

Closing out her discussion on novel therapeutics in endometrial cancer, Ritu Salani, MD, MBA, shares excitement for ongoing evolutions within the treatment landscape.

Key opinion leader Alicia Morgans, MD, MPH, considers the role of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer management.

Expert perspectives on the VISION and TheraP trials, which utilized lutetium Lu 177 vipivotide tetraxetan, also known as lutetium-177–PSMA-617, in the setting of metastatic castration-resistant prostate cancer.

Expert Ritu Salani, MD, MBA, reviews data from TROPiCS-03 and considers the potential role for antibody drug conjugates in patients with advanced endometrial cancer.

A brief review of clinical trial data from RAINBO and GY020, which tested adjuvant immunotherapy following radiation in patients with endometrial cancer.

Focused discussion on the CARD trial, which utilized cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer.

Focused discussion on single-agent immunotherapy in patients with advanced endometrial cancer following data from the PHAEDRA and DOMENICA clinical trials.

Following her review of a patient case of metastatic castration-resistant prostate cancer, Alicia Morgans, MD, MPH, highlights the range of treatment options in this setting.

Expert perspectives on the RUBY and GY018 trials, which tested dostarlimab and pembrolizumab, respectively, in combination with chemotherapy in patients with advanced or recurrent endometrial cancer.

Expert oncologist Alicia Morgans, MD, MPH, shares details on the diagnosis and management of a patient with metastatic castration-resistant prostate cancer.

Sheng F. Cai, MD, PhD, discusses the results of the BEAT AML master trial in patients with acute myeloid leukemia.

Leslie Randall, MD, MAS, offers closing thoughts on the future trajectory of ovarian cancer treatment.

An expert gynecologic oncologist comments on recent revisions to FDA-approved indications for PARP inhibitors in the treatment of ovarian cancer.

Leslie Randall, MD, MAS, reviews recent long-term data on PARP inhibitors in the treatment of ovarian cancer.

Clinical insights on how to manage adverse events for patients with ovarian cancer who are receiving PARP inhibitors.

An expert on ovarian cancer discusses factors that influence PARP inhibitor selection, when to initiate maintenance therapy, and how to counsel patients on PARP inhibitors.

Leslie Randall, MD, MAS, reviews the available treatment options for BRCA-mutated advanced ovarian cancer.

An overview of guideline recommendations for molecular testing in ovarian cancer.

Leslie Randall, MD, MAS, presents the case of a 55-year-old woman with BRCA-mutated ovarian cancer and provides her initial impressions.